Dashboard
Manage Tickers

ATNMActinium Pharmaceuticals, Inc.

NYSE actiniumpharma.com


$ 8.73 $ -0.17 (-1.91 %)    

Friday, 10-May-2024 15:59:43 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 443.58 $ 0.17 (0.04 %)
DIA $ 395.04 $ 1.18 (0.3 %)
SPY $ 520.76 $ 0.67 (0.13 %)
TLT $ 90.33 $ 0.00 (0 %)
GLD $ 217.08 $ -0.10 (-0.05 %)
$ 8.73
$ 8.77
$ 0.00 x 0
$ 0.00 x 0
$ 8.42 - $ 8.77
$ 4.00 - $ 9.86
196,229
na
260.01M
$ 0.78
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 04-26-2024 03-31-2024 10-Q
2 03-29-2024 12-31-2023 10-K
3 11-02-2023 09-30-2023 10-Q
4 08-14-2023 06-30-2023 10-Q
5 05-15-2023 03-31-2023 10-Q
6 03-31-2023 12-31-2022 10-K
7 11-14-2022 09-30-2022 10-Q
8 08-12-2022 06-30-2022 10-Q
9 05-13-2022 03-31-2022 10-Q
10 03-25-2022 12-31-2021 10-K
11 11-12-2021 09-30-2021 10-Q
12 07-30-2021 06-30-2021 10-Q
13 05-14-2021 03-31-2021 10-Q
14 03-31-2021 12-31-2020 10-K
15 10-23-2020 09-30-2020 10-Q
16 08-14-2020 06-30-2020 10-Q
17 06-30-2020 03-31-2020 10-Q
18 05-08-2020 12-31-2019 10-K
19 11-12-2019 09-30-2019 10-Q
20 08-09-2019 06-30-2019 10-Q
21 05-10-2019 03-31-2019 10-Q
22 03-15-2019 12-31-2018 10-K
23 11-09-2018 09-30-2018 10-Q
24 08-09-2018 06-30-2018 10-Q
25 05-10-2018 03-31-2018 10-Q
26 03-16-2018 12-31-2017 10-K
27 11-03-2017 09-30-2017 10-Q
28 08-04-2017 06-30-2017 10-Q
29 05-15-2017 03-31-2017 10-Q
30 03-16-2017 12-31-2016 10-K
31 10-28-2016 09-30-2016 10-Q
32 07-29-2016 06-30-2016 10-Q
33 05-10-2016 03-31-2016 10-Q
34 03-11-2016 12-31-2015 10-K
35 10-30-2015 09-30-2015 10-Q
36 08-07-2015 06-30-2015 10-Q
37 05-08-2015 03-31-2015 10-Q
38 03-16-2015 12-31-2014 10-K
39 10-31-2014 09-30-2014 10-Q
40 08-12-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

actinium-announces-announced-five-abstracts-accepted-for-presentation-at-2024-snmmi-annual-meeting
Actinium Announces Announced Five Abstract...
05/13/2024 12:38:35

-       Iomab-B and Actimab-A are the only targeted radiotherapies in for acute myeloid leukemia addressing different parts of ...

actinium-announces-kol-webinar-to-highlight-recently-announced-iomab-act-trial-with-leading-fda-approved-commercial-car-t-cell-therapy-being-led-by-the-university-of-texas-southwestern
Actinium Announces KOL Webinar To Highligh...
05/07/2024 12:21:50

Dr. Farrukh Awan, Professor of Medicine, Division of Hematology Oncology at University of Texas Southwestern and Principal Inve...

hc-wainwright--co-reiterates-buy-on-actinium-pharma-maintains-50-price-target
HC Wainwright & Co. Reiterates Buy on Acti...
05/02/2024 17:13:10

HC Wainwright & Co. analyst Joseph Pantginis reiterates Actinium Pharma (AMEX:ATNM) with a Buy and maintains $50 price t...

cantor-fitzgerald-reiterates-overweight-on-actinium-pharma-maintains-21-price-target
Cantor Fitzgerald Reiterates Overweight on...
04/30/2024 14:14:58

Cantor Fitzgerald analyst Kristen Kluska reiterates Actinium Pharma (AMEX:ATNM) with a Overweight and maintains $21 price ta...

hc-wainwright--co-reiterates-buy-on-actinium-pharma-maintains-50-price-target
HC Wainwright & Co. Reiterates Buy on Acti...
04/29/2024 10:10:05

HC Wainwright & Co. analyst Joseph Pantginis reiterates Actinium Pharma (AMEX:ATNM) with a Buy and maintains $50 price t...

actinium-highlights-ability-of-iomab-b-to-overcome-high-risk-tp53-mutation-resulting-in-improvement-in-overall-survival-in-patients-with-active-relapsed-refractory-aml-at-the-european-bone-marrow-transplant-annual-meeting
Actinium Highlights Ability Of Iomab-B To ...
04/18/2024 12:11:26

-- Iomab-B led bone marrow transplant produced high rates of complete remission and durable complete remission regardless of TP...

hc-wainwright--co-reiterates-buy-on-actinium-pharma-maintains-50-price-target
HC Wainwright & Co. Reiterates Buy on Acti...
04/01/2024 14:16:58

HC Wainwright & Co. analyst Joseph Pantginis reiterates Actinium Pharma (AMEX:ATNM) with a Buy and maintains $50 price t...

cantor-fitzgerald-reiterates-overweight-on-actinium-pharma-maintains-21-price-target
Cantor Fitzgerald Reiterates Overweight on...
04/01/2024 12:24:46

Cantor Fitzgerald analyst Kristen Kluska reiterates Actinium Pharma (AMEX:ATNM) with a Overweight and maintains $21 price ta...

actinium-announces-iomab-b-phase-3-sierra-trial-results-demonstrating-survival-benefit-in-high-risk-relapsed-or-refractory-acute-myeloid-leukemia-patients-with-tp53-mutations-accepted-for-oral-presentation-at-the-european-bone-marrow-transplant-annual-meeting
Actinium Announces Iomab-B Phase 3 SIERRA ...
04/01/2024 12:09:44

-  The SIERRA results demonstrate Iomab-B's ability to overcome the negative impact of a TP53 mutation in patients who othe...

hc-wainwright--co-reiterates-buy-on-actinium-pharma-maintains-50-price-target
HC Wainwright & Co. Reiterates Buy on Acti...
03/26/2024 16:14:50

HC Wainwright & Co. analyst Joseph Pantginis reiterates Actinium Pharma (AMEX:ATNM) with a Buy and maintains $50 price t...

actinium-announces-clinical-trial-to-study-iomab-act-targeted-radiotherapy-conditioning-with-leading-fda-approved-commercial-car-t-cell-therapy
Actinium Announces Clinical Trial to Study...
03/26/2024 11:21:51

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjuga...

maxim-group-maintains-buy-on-actinium-pharma-raises-price-target-to-30
Maxim Group Maintains Buy on Actinium Phar...
03/19/2024 16:59:29

Maxim Group analyst Jason McCarthy maintains Actinium Pharma (AMEX:ATNM) with a Buy and raises the price target from $20 to ...

watching-actinium-pharmaceuticals-hc-wainwright-first-take-says-appetite-remains-high-for-radiopharmaceuticals-we-see-actinium-as-ripe-for-takeout-and-believes-it-is-receiving-ma-interest
Watching Actinium Pharmaceuticals; HC Wain...
03/19/2024 15:24:58

hc-wainwright--co-maintains-buy-on-actinium-pharma-maintains-50-price-target
HC Wainwright & Co. Maintains Buy on Actin...
03/19/2024 15:19:10

HC Wainwright & Co. analyst Joseph Pantginis maintains Actinium Pharma (AMEX:ATNM) with a Buy and maintains $50 price ta...

actinium-pharmaceuticals-disclosed-the-launch-of-strategic-initiative-focused-on-the-manufacture-of-the-highly-sought-after-medical-isotope-actinium-225-ac-225
Actinium Pharmaceuticals Disclosed The Lau...
03/14/2024 10:11:56

hc-wainwright--co-maintains-buy-on-actinium-pharma-maintains-50-price-target
HC Wainwright & Co. Maintains Buy on Actin...
03/11/2024 14:37:57

HC Wainwright & Co. analyst Joseph Pantginis maintains Actinium Pharma (AMEX:ATNM) with a Buy and maintains $50 price ta...

actinium-pharmaceuticals-has-launched-a-strategic-initiative-focused-on-the-manufacture-of-medical-isotope-actinium-225-leveraging-its-propriety-cyclotron-based-method
Actinium Pharmaceuticals Has Launched A St...
03/11/2024 11:46:37

actinium-announces-iomab-b-markedly-increases-long-term-survival-in-older-patients-with-active-relapsedrefractory-acute-myeloid-leukemia-in-phase-3-sierra-trial-at-2024-tandem-meetings--transplantation--cellular-therapy-meetings-of-astct-and-cibmtr
Actinium Announces Iomab-B Markedly Increa...
02/26/2024 12:38:42

actinium-highlights-improved-survival-with-iomab-b-in-tp53-positive-relapsed-refractory-acute-myeloid-leukemia-patients-in-sierra-trial-and-other-presentations-at-2024-transplantation--cellular-therapy-meetings-of-astct-and-cibmtr
Actinium Highlights Improved Survival With...
02/23/2024 12:43:56

12-health-care-stocks-moving-in-fridays-after-market-session
12 Health Care Stocks Moving In Friday's A...
02/09/2024 21:31:09

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION